Global Revenue Growth Dynamics:
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.
Get Free Sample Copy of Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724
Key Market Players
The prominent players in the autoinjectors industry are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany), Meridian Medical Technologies, Inc. (US), Roche Diagnostics (Switzerland), Bespak (UK), Bayer (Germany), SHL Medical (Switzerland), Haselmeier (Switzerland), Owen Mumford (UK), Ravimed (Poland), Medeca Pharma AB (Sweden), Cambridge Consultants Ltd. (UK), Flex (US), SMC Ltd. (US), and Promius Pharma (US).
AbbVie
AbbVie markets its products worldwide through wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The company is also entering into licensing arrangements, strategic alliances, co-promotion arrangements, co-development and co-marketing agreements, and joint ventures.
Amgen
Amgen is engaged in the discovery, development, manufacturing, and marketing of innovative human therapeutics. The company focuses on producing innovative medicines, expanding its global geographic reach, enhancing next-generation biomanufacturing, improving drug delivery systems, and branded biosimilars.
Eli Lilly and Company
Eli Lilly and Company provides autoinjectors for GLP-1 analogue for diabetes and psoriatic arthritis. The company’s wide presence across the globe also plays a very important role in securing its position in the market. To strengthen its position in the market, the company pursues the strategies of product launches and expansions. Innovation is an integral part of the company. Moreover, the company has witnessed tremendous marginal growth in the last three years.
Curious about this latest version of the report? Obtain Report Details @ https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html
AutoInjector Market Segmentation
The research report categorizes the autoinjectors market into the following segments and sub-segments:
By Therapy
- Rheumatoid Arthritis
- Multiple Sclerosis
- Diabetes
- Anaphylaxis
- Other Therapies
By Type
- Disposable Autoinjectors
- Reusable Autoinjectors
By Route of Administration
- Subcutaneous
- Intramuscular
By End User
- Home Care Settings
- Hospitals & Clinics
- Ambulatory Care Settings
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Purchase This Market Research Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=173991724
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
